Translation to Portuguese and Validation of the Douleur Neuropathique 4 Questionnaire

Santos, Jamile G.; Brito, Jacilene O.; Andrade, Daniel Ciampi de; Kaziyama, Viviane M.; Ferreira, Kuitéria Ribeiro; Souza, Israel; Teixeira, Manoel Jacobsen; Bouhassira, Didier; Baptista, Abrahão Fontes

doi:10.1016/j.jpain.2009.09.014

Cited by 134 publications

(132 citation statements)

References 11 publications

Supporting

Mentioning

110

Contrasting

Unclassified

Order By: Relevance

“…After clinical examination, patients completed the "Douleur neuropathique en 4 questions" (DN4) which serves to identify patients with neuropathic pain and consists of 7 items related to symptoms and 3 related to clinical examination. The DN4 is easy to score, and a total score of 4 out of 10 or higher suggests neuropathic pain [16,17]. The DN4 has been used in large epidemiological studies to estimate the prevalence of neuropathic pain.…”

Section: Methodsmentioning

confidence: 99%

Pain and Its Consequences in Quality of Life: A Study with WHOQOL-Bref in Leprosy Patients with Neuropathic Pain

Reis

Gomes

Rodrigues

et al. 2013

ISRN Tropical Medicine

View full text Add to dashboard Cite

Chronic neuropathic pain emerges as a challenge in the treatment of leprosy patients after multidrug therapy discharge. The aim of this study was to determine the quality of life and its repercussions in leprosy patients with chronic pain. We studied male and female patients with chronic neuropathic pain in the last year. Neuropathic pain was confirmed using Douleur Neuropathique en 4 (DN4) and its intensity evaluated by visual analogue scale (VAS). A general questionnaire was applied to evaluate quality of life (WHOQOL-bref). Statistical analyses were composed by descriptive and central tendency. Spearman correlation was used to identify the relation between pain intensity, quality of life domains, and facets. Multiple linear regressions were performed to verify the influence of pain intensity on each facet. Neuropathic pain patients scored worst in physical and environment domains. The low facets were related to pain and discomfort, thinking and concentration, sexual activity, and recreation opportunities. Pain intensity has a high negative influence on psychological domain and recreation opportunities. These findings should contribute to the development of rehabilitation programs considering patients needs to improve their quality of life and true social reintegration.

show abstract

Section: Methodsmentioning

confidence: 99%

Pain and Its Consequences in Quality of Life: A Study with WHOQOL-Bref in Leprosy Patients with Neuropathic Pain

Reis

Gomes

Rodrigues

et al. 2013

ISRN Tropical Medicine

View full text Add to dashboard Cite

show abstract

“…Assessments took place 1 week after each OXA infusion at planned visits and during the follow-up period by research nurses not implicated in OXA administration. The presence of neuropathic pain characteristics was assessed by the Douleur Neuropathique-4 (0–10, positive ≥4) [31]. Neuropathic Pain Symptom Inventory (0–100) was used for neuropathic pain profiling [32], [33].…”

Section: Trial Informationmentioning

confidence: 99%

Pregabalin for the Prevention of Oxaliplatin-Induced Painful Neuropathy: A Randomized, Double-Blind Trial

et al. 2017

Self Cite

View full text Add to dashboard Cite

Lessons Learned. Pregabalin is a medication that can decrease neuronal hyperexcitability, relieve neuropathic pain, and reach stable plasma levels after a titration period of only a few days.Its use during oxaliplatin infusions was not able to decrease the incidence of chronic, oxalipaltin‐related neuropathic pain, compared with placebo.Background.Patients with colorectal cancer (CRC) receiving oxaliplatin (OXA) develop acute and chronic painful oxaliplatin‐induced peripheral neuropathy (OXAIPN). Acute and chronic OXA‐related neuropathies have different pathophysiological bases, but both lead to a common phenomenon: central sensitization (CS) of nociceptive neuronal networks, leading to increased sensitivity (hyperlgesia, allodynia) in the somatosensory system, the common ground of chronic neuropathic pain. Because CS is related to increased risk of painful OXAIPN, we hypothesized that preemptive use of the anti‐hyperalgesic drug pregabaline (known to decrease CS) during OXA infusions would decrease the incidence of chronic OXAIPN.Methods.Pain‐free, chemotherapy‐naïve CRC patients receiving at least one cycle of modified‐FLOX [5‐FU(500 mg/m2)+leucovorin(20 mg/m2)/week for] 6 weeks+oxaliplatin(85 mg/m2) at weeks 1‐3‐5 every 8 weeks] were randomized (1:1) into the study. Patients received either pregabalin or placebo for 3 days before and 3 days after each OXA infusion and were followed for up to 6 months. Clinical assessments were performed at baseline, at the end of chemotherapy, and after the follow‐up period. The main outcome was average pain at the last visit assessed by the visual analogic scale (0–10) item of the Brief Pain Inventory (BPI). Secondary endpoints were presence of neuropathic pain according to the Douleur Neuropathique‐4 (DN‐4), pain dimensions (short‐ form McGill Pain Questionnaire [MPQ]), Neuropathic Pain Symptom Inventory (NPSI), and changes in nerve conduction studies (NCS) and side effect profile.Results.One hundred ninety‐nine patients (57.0 ± 10.7 years old, 98 female, 101 male) were randomized. Data from 56 patients were not included in the analyses (as they did not receive at least one full cycle of modified FLOX). Data from 78 patients in the pregabalin group and 65 patients in the placebo group were retained for analyses. At the last visit, pain intensity in the pregabalin group was 1.03 (95% confidence interval [CI] = 0.79–1.26), and 0.85 (95% CI = 0.64–1.06) in the placebo group, which did not reach significance. Scores from the BPI, MPQ, DN‐4, NPSI, and NCS and side‐effect profiles and incidence of death did not differ between groups. Quality of life (QoL) score did not differ between groups (placebo = 76.9 ± 23.1, pregabalin group 79.4 ± 20.6). Mood scores were not significantly different between groups (placebo 9.7 [8.1–11.2]; pregabalin 6.8 [5.6–8.0]).Conclusion.The preemptive use of pregabalin during OXA infusions was safe, but did not decrease the incidence of chronic pain related to OXAIPN.

show abstract

“…The identification of the neuropathic component depends on thorough history and physical evaluation, in addition to complementary exams 15 . NP is spontaneous and may have specific clinic characteristics, such:…”

Section: Clinical Presentationmentioning

confidence: 99%

Low back pain

Stump¹,

Kobayashi²,

Campos³

2016

Revista Dor

View full text Add to dashboard Cite

Translation to Portuguese and Validation of the Douleur Neuropathique 4 Questionnaire

Cited by 134 publications

References 11 publications

Pain and Its Consequences in Quality of Life: A Study with WHOQOL-Bref in Leprosy Patients with Neuropathic Pain

Pain and Its Consequences in Quality of Life: A Study with WHOQOL-Bref in Leprosy Patients with Neuropathic Pain

Pregabalin for the Prevention of Oxaliplatin-Induced Painful Neuropathy: A Randomized, Double-Blind Trial

Low back pain

Contact Info

Product

Resources

About